Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rituximab shows promise for long-term control of rare blistering skin disease

NCT ID NCT03790293

Disease control Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 80 patients with pemphigus, a rare autoimmune disease that causes painful blisters on skin and mucous membranes. Researchers wanted to see how safe and effective rituximab (a drug that targets certain immune cells) is over the long term, compared to standard high-dose steroids. The goal was to check for serious side effects, relapse rates, and how the immune system changes years after treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rituximab
What this could lead to
If successful, this could confirm that rituximab provides long-term remission with fewer side effects than standard steroids.
What could go wrong
This is a follow-up study, not a new treatment trial. It may show that benefits fade over time or that long-term immune suppression raises infection risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

80 people

The number who actually took part.

Started

Nov 2018

Finished

Apr 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient included in the RITUXIMAB 3 study * Major patient who has read and understood the newsletter and signed the consent form Exclusion Criteria: * Person deprived of liberty by an administrative or judicial decision * Person placed under the safeguard of justice * Person under tutorship or curators * Pregnant or lactating woman

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autoimmune diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune disease pemphigus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autoimmune diseases

Contacts and locations

Locations

  • Ah-Hp Cochin

    Paris, 75006, France

  • Ap-Hm La Timone

    Marseille, 13385, France

  • Ap-Hp Avicenne

    Bobigny, 93000, France

  • Ap-Hp Bichat

    Paris, 75018, France

  • Ap-Hp Cochin

    Paris, 75014, France

  • Ap-Hp Henri Mondor

    Créteil, 94010, France

  • Ap-Hp Saint-Louis

    Paris, 75010, France

  • Ch Le Mans

    Le Mans, 72037, France

  • Chru Lille

    Lille, 59000, France

  • Chu Angers

    Angers, 49100, France

  • Chu Bordeaux

    Bordeaux, 33076, France

  • Chu Brest

    Brest, 29200, France

  • Chu Clermont-Ferrand

    Clermont-Ferrand, 63100, France

  • Chu Dijon

    Dijon, 21000, France

  • Chu Limoges

    Limoges, 87000, France

  • Chu Montpellier

    Montpellier, 34090, France

  • Chu Nantes

    Nantes, 44000, France

  • Chu Reims

    Reims, 51092, France

  • Chu Rennes

    Rennes, 35000, France

  • Chu Rouen

    Rouen, 76031, France

  • Chu Saint-Etienne

    Saint-Etienne, 42270, France

  • Chu Toulouse

    Toulouse, 31059, France

  • Chu Tours

    Tours, 37000, France

  • Hcl Ch Lyon Sud

    Lyon, 69310, France

  • Hcl Edouard Herriot

    Lyon, 69003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.